We recently compiled a list of the 10 Dogs of the Dow Dividend Stocks to Invest in. In this article, we are going to take a ...

The big pharma is paying Hansoh $112 million upfront to place its bet on oral GLP-1 receptor agonist HS-1035, with another $1 ...

A charter school with a focus on life sciences curriculum has gotten approved from town leaders in Holly Springs.

Nonspecific anti-inflammatories like steroids might be entirely sidelined for mild-to-moderate chronic hand eczema now that three targeted topical agents are available.

Amgen's leukemia drug Blincyto infringes patents owned by Germany's Lindis Biotech, a Delaware federal jury said in a verdict ...

Merck has signed a licensing deal worth up to $2 billion for Chinese biotech Hansoh Pharma's experimental oral drug to treat ...

Pain has really been out of favor in the industry up until very recently,” said John Mulcahy, SiteOne Therapeutics’ CEO. The ...

Viridian's veligrotug shows promising results in treating TED patients, setting the stage for future growth in the ...

Merck signed a deal worth up to $2 billion with Hansoh Pharma to develop and sell the Chinese biotech's oral obesity drug ...

Merck on Wednesday signed a deal worth up to $2 billion with Hansoh Pharma to develop and sell the Chinese biotech's ...

Truist Financial analyst Srikripa Devarakonda assigned a Buy rating to the stock today. The company’s shares closed yesterday at $4.64.Pick the ...

Merck (MRK) stock gains as company enters a global licensing deal with Hansoh Pharma to develop an oral obesity drug. Read ...